Clinical Trials · NCT01785771
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c
- Phase
- Phase 3
- Recruitment status
- Terminated
- Sponsor
- Intarcia Therapeutics
- Enrollment
- 100
- Start date
- May 2013
- Locations
- 51 sites, United States
- Primary endpoint
- Change in HbA1c between Week 39 and Day 0